Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial

Title: Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial
Authors: Molina, Jean-Michel; Charreau, Isabelle; Chidiac, Christian; Pialoux, Gilles; Cua, Eric; Delaugerre, Constance; Capitant, Catherine; Rojas-Castro, Daniela; Fonsart, Julie; Berçot, Béatrice; Bébéar, Cécile; Cotte, Laurent; Robineau, Olivier; Raffi, Francois; Charbonneau, Pierre; Aslan, Alexandre; Chas, Julie; Niedbalski, Laurence; Spire, Bruno; Sagaon-Teyssier, Luis; Carette, Diane; Mestre, Soizic Le; Doré, Veronique; Meyer, Laurence
Contributors: Service des Maladies Infectieuses et Tropicales CHU Saint Louis; Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales; Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM); Essais Thérapeutiques et Maladies Infectieuses; Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM); Hospices Civils de Lyon (HCL); CHU Tenon AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Département des Maladies Infectieuses CHU Nice (Hôpital de l'Archet); Hôpital l'Archet - CHU de Nice; Service de microbiologie Saint-Louis; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); AIDES Pantin, France (Mission Innovation Recherche Expérimentation); AP-HP Groupe hospitalier Lariboisière - Fernand-Widal Paris; Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)); Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM); Laboratoire de Microbiologie AP-HP Groupe Hospitalier Lariboisière; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal APHP; Laboratoire de Bactériologie CHU Bordeaux (Centre National des Infections Sexuellement Transmissibles Bactériennes); Université Bordeaux Segalen - Bordeaux 2-Centre National de Référence des Chlamydia; Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL); Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Département des Maladies Infectieuses CH Tourcoing (Hôpital Gustave Dron); Centre Hospitalier Gustave Dron Tourcoing -Centre Hospitalier de Tourcoing; Centre d’Investigation Clinique de Nantes (CIC Nantes); Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes); Département des Maladies Infectieuses CHU Nantes; Centre hospitalier universitaire de Nantes (CHU Nantes); Département des maladies infectieuses; Institut de Veille Sanitaire (INVS); Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD); Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM); ANRS France Recherche Nord & sud Sida-hiv hépatites; ANRS IPERGAY Study Group : Pintado C, Loze B, Gatey C, Ponscarme D, Penot P, Veron R, Delgado J, Dalle E, Parlier S, Madelaine I, Danet M, Mahjoub N, Mezreb N, Moudachirou K, Morel S, Conort G, Lorho F, Meunier M, Rozenbaum W, Monfort C, Foucoin J, Boissavy B, Cousseau S, Huon S, Danet M, Djessima A, Berrebi V, Adda A, le Nagat S, Zarka L, Berdougo J, Mzoughi N, Clement F, Decouty A, Chapolard C, Godinot M, Adouard-Groslafeige C, Koffi J, Pansu A, Becker A, Pailhes S, Bonnet F, Jeanblanc F, Brochier C, Teruin X, Rouby S, Gilly L, Etienne C, Tolonin F, Breaud S, Péchenot V, Bagge S, Cepitelli T, Roger PM, Rosenthal E, Cheret A, Cornavin P, Vandamme S, Lambec J, Dumon N, Leclanche O, Huleux T, Biekre R, Melliez H, Bazus H, Pasquet A, Bernaud C, Besnier M, Bonnet B, Hall N, Cavellec M, Hue H, Larmet L, Colas M, Choquet R, Fouéré S, Netzer E, Leturque N, Binesse J, Foubert V, Saouzanet M, Euphrasie F, Guillon B, Saïdi Y, Suzan M, Cattin G, Demoulin B, Lorente N.
Source: ISSN: 1473-3099.
Publisher Information: HAL CCSD; Elsevier Science; The Lancet Pub. Group, 2001-
Publication Year: 2018
Subject Terms: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie; envir; socio
Description: International audience ; BACKGROUND:Increased rates of sexually transmitted infections (STIs) have been reported among men who have sex with men. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of STIs.METHODS:All participants attending their scheduled visit in the open-label extension of the ANRS IPERGAY trial in France (men aged 18 years or older having condomless sex with men and using pre-exposure prophylaxis for HIV with tenofovir disoproxil fumarate plus emtricitabine) were eligible for inclusion in this open-label randomised study. Participants were randomly assigned (1:1) at a central site to take a single oral dose of 200 mg doxycycline PEP within 24 h after sex or no prophylaxis. The primary endpoint was the occurrence of a first STI (gonorrhoea, chlamydia, or syphilis) during the 10-month follow-up. The cumulative probability of occurrence of the primary endpoint was estimated in each group with the Kaplan-Meier method and compared with the log-rank test. The primary efficacy analysis was done on the intention-to-treat population, comprising all randomised participants. All participants received risk-reduction counselling and condoms, and were tested regularly for HIV. This trial is registered with ClinicalTrials.gov number, NCT01473472.FINDINGS:Between July 20, 2015, and Jan 21, 2016, we randomly assigned 232 participants (n=116 in the doxycycline PEP group and n=116 in the no-PEP group) who were followed up for a median of 8·7 months (IQR 7·8-9·7). Participants in the PEP group used a median of 680 mg doxycycline per month (IQR 280-1450). 73 participants presented with a new STI during follow-up, 28 in the PEP group (9-month probability 22%, 95% CI 15-32) and 45 in the no-PEP group (42%, 33-53; log-rank test p=0·007). The occurrence of a first STI in participants taking PEP was lower than in those not taking PEP (hazard ratio [HR] 0·53; 95% CI 0·33-0·85; p=0·008). Similar results were observed for the occurrence of a first episode of chlamydia .
Document Type: article in journal/newspaper
Language: English
Relation: https://inserm.hal.science/inserm-02096653/file/PIIS1473309917307259.pdf; https://inserm.hal.science/inserm-02096653
Availability: https://inserm.hal.science/inserm-02096653/file/PIIS1473309917307259.pdf; https://inserm.hal.science/inserm-02096653
Rights: undefined
Accession Number: edsbas.58BFE3ED
Database: BASE